Article
KRAS mutation as the biomarker of response to chemotherapy and EGFR-TKIs in patients with advanced non-small cell lung cancer: clues for its potential use in second-line therapy decision making.
American journal of clinical oncology - 1 Feb 2015
Campos-Parra Alma D, Zuloaga Carlos, Manríquez María Eugenia Vazquez, Avilés Alejandro, Borbolla-Escoboza Jose, Cardona Andrés, Meneses Abelardo, Arrieta Oscar
Abstract excerpt
OBJETIVE: In patients with non-small cell lung cancer (NSCLC), knowledge of the epidermal growth factor receptor (EGFR) mutation status is fundamental for selecting the treatment involving EGFR-tyrosine kinase inhibitors (EGFR-TKIs). Little information is available regarding the response and progression-free survival (PFS) in platinum-based chemotherapy (CT) versus EGFR-TKIs in the presence or absence of KRAS...
Topics
- Adenocarcinoma
- Aged
- Antineoplastic Combined Chemotherapy Protocols
- Carboplatin
- Carcinoma, Non-Small-Cell Lung
- Cisplatin
- Disease-Free Survival
- ErbB Receptors
- Female